Testing the drug CBL0137 in people whose tumors came back or did not respond to treatment
Original title: CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is an early study that is still working out the right dose and looking for side effects.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This study is testing a drug called CBL0137 in people with solid tumors, brain and spine tumors, or lymphoma that came back or kept growing.
Who this trial is for. This trial is for people with solid tumors, including tumors of the brain and spine, or lymphoma. The cancer has either come back after treatment or did not respond to treatment. The trial is testing the best dose of a drug called CBL0137, its side effects, and whether it helps.
Where it stands. There are no results to share. The trial is still looking at the best dose, the side effects, and any possible benefit. Those answers are not in yet.
What this means, and what it doesn't
What it could mean: CBL0137 blocks signals that cells pass to each other inside the cell. Blocking those signals can change how a cell works, including how it divides and how it dies. That may kill cancer cells. This trial is one way to find out. Someone whose cancer came back or did not respond to treatment could ask their care team about it.
What it doesn't mean: This does not mean CBL0137 is a proven treatment. A trial is a test. We do not yet know if this drug helps people or how safe it is. Joining a trial is not a guarantee that you will be helped. It is not a promise of a cure.
Source: ClinicalTrials.gov, September 11, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.